Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This study tests a new drug called LM-108, given with or without another drug (penpulimab) plus chemotherapy, in people with advanced solid tumors. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 194 adults with tumors that have not…

This early-phase study tests a new drug called TQB6411 in people with advanced cancers that have not responded to other treatments. The drug is designed to attach to specific markers on cancer cells and deliver a toxin to kill them. The main goals are to find a safe dose and chec…

This phase 2 study tests whether adding TQB2868 and anlotinib to standard chemotherapy can help control pancreatic cancer that has spread. About 80 adults with pancreatic ductal adenocarcinoma who have not had prior treatment will receive the combination. The main goal is to see …

This phase 3 trial compares a new drug, TQB2102, against the standard TCbHP regimen in people with HER2-positive breast cancer before they have surgery. About 544 participants will receive one of the two treatments to see which is better at eliminating cancer in the breast and ly…

This study tests two experimental drugs, TQB2930 and TQB2102, given together to people with advanced solid tumors that have a protein called HER2. The goal is to find the best dose and see if the combination can shrink tumors. About 178 adults aged 18 to 75 with HER2-positive adv…

This phase 3 study tests whether a new drug called TQB2930, combined with chemotherapy, works better than the standard drug trastuzumab plus chemotherapy for people with advanced HER2-positive breast cancer. About 416 adults aged 18-75 who have already tried at least two prior an…

This early-phase study tests a new drug called TQB2934, given as a shot under the skin, for people with multiple myeloma (a type of blood cancer). The drug works like a bridge, bringing immune T-cells close to cancer cells so the T-cells can kill them. The main goals are to check…

This study tests a new drug called TQB2102 for people with a rare bile duct cancer that has spread and has a specific marker (HER2-positive). About 102 adults aged 18-75 will receive the drug to see if it shrinks tumors and how safe it is. The goal is to control the disease, not …

This study tests an experimental drug called TQH3906 in adults with moderate-to-severe ulcerative colitis or Crohn's disease. About 135 participants will receive either the drug or a placebo for 12 weeks to see if it safely reduces inflammation and improves symptoms. The goal is …

This phase 2 trial tests TQB2102, a drug that delivers a powerful toxin directly to cancer cells with a specific genetic change (HER2 abnormality). The study aims to see if the drug can shrink tumors in 270 adults with advanced non-small cell lung cancer that cannot be removed by…